Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsids
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, unveiled its preclinical gene therapy program for X-linked retinoschisis (XLRS), a monogenic disease caused by mutations in the RS1 gene.
Here’s How Seasonal Affective Disorder Can Make Sleep Worse—And What You Can Try, According to a Therapist
Sherry Benton, founder of TAO Connect, a UF Innovate | Accelerate startup, shares why seasonal affective disorder occurs and ways to overcome it.
Rain Neuromorphics Tapes Out Demo Chip for Analog AI
UF startup and UF Innovate | Accelerate graduate Rain Neuromorphics, which incubated at The Hub, has taped out a demonstration chip for its brain-inspired analog architecture that employs a 3D array of randomly-connected memristors to compute neural network training and inference at extremely low power.
AavantiBio Furthers Strategic Partnership With University of Florida To Research and Develop Next Generation Gene Therapy Capsids
UF startup and UF Innovate | The Hub resident AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, announced it is partnering with the University of Florida to research and develop next generation gene therapy capsids with the goal of creating safer, more effective, and tissue specific gene therapies.
ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations
UF startup ViewRay, Inc., a leading medical technology company that provides groundbreaking MRI-guided radiation therapy, announced that the company has received acceptance from the FDA on their recent submission for new MRIdian features focused on enhancing on-table adaptive workflow efficiency and expanding clinical utility.
Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216, Its First Generation Antiapoptotic Protein Targeted Degradation (APTaD™) Compound, in Patients With Relapsed or Refractory Malignancies
UF startup Dialectic Therapeutics, Inc., a Texas-based clinical-stage biotechnology company focused on creating innovative new technologies to treat cancer, announced the dosing of the first patient in a first-in-human, dose-escalation Phase 1 trial evaluating DT2216, the first generation compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD™) technology, in patients with relapsed or refractory solid tumor and hematologic malignancies.
Interview with Juan Tomás Hernani, CEO of SATLANTIS
Avión Revue, an international aviation news site, interviewed Hernani about his journey licensing the technology with the University of Florida and upcoming projects.
Oragenics Awarded a $250,000 Grant From the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., announced that it was awarded a small business innovation research grant in the amount of $250,000 (Computer-aided Design for Improved Lantibiotics R41GM136034) for the company’s continued research and development of lantibiotics, including its collaborative program with the Biomolecular Sciences Institute at Florida International University (FIU).
Cannabix Technologies Ramps Up Beta Testing With THC Breathalyzer and Ships Additional Devices
UF startup Cannabix Technologies Inc., developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, reports that it is ramping up subject beta testing in a high-volume clinic in the Northwestern US and will ship an additional THC Breath Analyzer (THCBA) unit to the site.
AGTC: The New Leader in Ocular Gene Therapy With Sue Washer
Sue Washer, president and CEO of Applied Genetic Technologies Corporation (AGTC), discusses ocular gene therapy with the Eye Care Insider podcast host Joshua Mali, MD.
